Bronchiolitis

Poletti, Venerino; Casoni, Gian Luca; Zompatori, Maurizio; Chilosi, Marco

doi:10.1159/000102699

Cited by 31 publications

(67 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Her forced expiratory volume in 1 s was 35% of predicted normal with no response to inhaled bronchodilator. Diffuse panbronchiolitis is an unusual form of bronchiolitis of unknown cause described mainly in Asia, particularly in Japanese adults, and is characterized by bronchiolar inflammation and chronic sinusitis [36,37,38 ]. Few cases occurring in non-Asian patients have been described in the US and Europe [37,38 ].…”

Section: Primary Bronchiolar Disordersmentioning

confidence: 99%

“…On chest radiography, diffuse panbronchiolitis is characterized by diffuse small (up to 5 mm in diameter), illdefined nodular opacities most prominent over the lung bases and symmetrically distributed. In late stages, the radiographic features of cylindrical bronchiectasis and hyperinflation may become evident [37,38 ]. Findings on HRCT depend on the stage of the disease and include centrilobular nodules, distal branching structures, thickened and ectatic bronchioles, bronchiectasis, and peripheral air trapping [38 ].…”

Section: Primary Bronchiolar Disordersmentioning

confidence: 99%

See 1 more Smart Citation

Classification and approach to bronchiolar diseases

Ryu

2006

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

In the clinical approach to a patient with bronchiolar disease, primary bronchiolar disorders should be distinguished from predominantly parenchymal or large airway processes with bronchiolar involvement. The number of patterns of bronchiolar response to injury is limited and these patterns are generally non-specific in regard to cause. Appropriate diagnosis and management of patients with bronchiolar disorders depend on judicious correlation of clinical, physiologic, and morphologic manifestations.

show abstract

Section: Primary Bronchiolar Disordersmentioning

confidence: 99%

Section: Primary Bronchiolar Disordersmentioning

confidence: 99%

Classification and approach to bronchiolar diseases

Ryu

2006

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

show abstract

“…Although DPB has been frequently compared to CF, and has served as a model for the implementation of antiinflammatory therapies in CF lung disease [33], it is known to be a separate clinicopathologic entity that is not characterized by pancreatic exocrine insufficiency or obstructive azoospermia and male infertility. DPB is not associated with the ΔF508 mutation [37], although the contribution of minor CFTR mutations has not been excluded [38].…”

Section: Non-cftr-related Diseasesmentioning

confidence: 97%

Atypical Cystic Fibrosis and CFTR-Related Diseases

Paranjape

Zeitlin

2008

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Cystic fibrosis (CF), which is among the most common life-shortening recessive illnesses, is caused by mutations of the CF transmembrane conductance regulator (CFTR) and typically involves chronic infection and progressive obstruction of the respiratory tract as well as pancreatic exocrine insufficiency. Disease severity, to some extent, correlates with organ sensitivity to CFTR dysfunction and to the amount of functional protein, which is influenced by the type of mutation. Atypical CF represents approximately 2% of affected individuals, and includes cases presenting in adolescence or adulthood with pancreatic exocrine sufficiency, normal or borderline sweat chloride concentrations, or with a single predominant clinical feature. This review briefly describes diagnostic methods and phenotypic characteristics of classic and atypical CF, as well as CFTR-related diseases, conditions in which mutated CFTR may contribute to the pathogenesis but do not strictly fit established diagnostic criteria.

show abstract

“…In chronic respiratory diseases, including COPD, DPB, and cystic fibrosis, or acute respiratory diseases, such as infection with M. pneumonia or C. pneumoniae, over-activated T lymphocytes produce pro-inflammatory cytokines or proliferate in situ in the lower airways or pulmonary parenchyma, which contributes substantially to the pathogenesis of the diseases [6,10,32,[42][43][44][45][46]97]. As we recently demonstrated in kidneys with chronic inflammation [61,98], the activity of T lymphocytes and their in situ proliferation within the peripheral organs are largely dependent on the activity of the Kv1.3-channels and their expression level.…”

Section: In Respiratory Diseasesmentioning

confidence: 99%

Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases

2015

View full text Add to dashboard Cite

T lymphocytes predominantly express delayed rectifier K(+)-channels (Kv1.3) in their plasma membranes. Patch-clamp studies revealed that the channels play crucial roles in facilitating the calcium influx necessary to trigger lymphocyte activation and proliferation. Using selective channel inhibitors in experimental animal models, in vivo studies further revealed the clinically relevant relationship between the channel expression and the development of chronic respiratory diseases, in which chronic inflammation or the overstimulation of cellular immunity in the airways is responsible for the pathogenesis. In chronic respiratory diseases, such as chronic obstructive pulmonary disease, asthma, diffuse panbronchiolitis and cystic fibrosis, in addition to the supportive management for the symptoms, the anti-inflammatory effects of macrolide antibiotics were shown to be effective against the over-activation or proliferation of T lymphocytes. Recently, we provided physiological and pharmacological evidence that macrolide antibiotics, together with calcium channel blockers, HMG-CoA reductase inhibitors, and nonsteroidal anti-inflammatory drugs, effectively suppress the Kv1.3-channel currents in lymphocytes, and thus exert anti-inflammatory or immunomodulatory effects. In this review article, based on the findings obtained from recent in vivo and in vitro studies, we address the novel therapeutic implications of targeting the lymphocyte Kv1.3-channels for the treatment of chronic or acute respiratory diseases.

show abstract

Bronchiolitis

Cited by 31 publications

References 0 publications

Classification and approach to bronchiolar diseases

Classification and approach to bronchiolar diseases

Atypical Cystic Fibrosis and CFTR-Related Diseases

Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases

Contact Info

Product

Resources

About